{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Stage+1%3A+Acetaminophen", "query": { "intervention": "Stage 1: Acetaminophen" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 129, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Stage+1%3A+Acetaminophen&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T22:23:35.654Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00899847", "title": "Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Transplantation, Homologous", "Transplantation, Autologous", "Multiple Myeloma", "Blood and Marrow Transplant (BMT)" ], "interventions": [ { "name": "Autologous peripheral blood stem cells (auto-PBSC) transplantation", "type": "PROCEDURE" }, { "name": "Allogeneic peripheral blood stem cells (allo-PBSC) transplantation", "type": "PROCEDURE" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Total lymphoid irradiation", "type": "RADIATION" }, { "name": "Rabbit anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "Mycophenolate Mofetil 250mg", "type": "DRUG" }, { "name": "Solumedrol", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 9, "start_date": "2009-05", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2017-10-20", "last_synced_at": "2026-09-25T22:23:35.654Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00899847" }, { "nct_id": "NCT02356159", "title": "Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes", "Hodgkin's Lymphoma", "Non-Hodgkin's Lymphoma", "Acute Leukemia", "Multiple Myeloma" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Conditioning chemotherapy", "type": "DRUG" }, { "name": "TMS", "type": "DRUG" }, { "name": "FLAG", "type": "DRUG" }, { "name": "EPOCH-F", "type": "DRUG" }, { "name": "Hematopoietic stem cell transplant", "type": "PROCEDURE" }, { "name": "Palifermin", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Epinephrine", "type": "DRUG" }, { "name": "IV Saline", "type": "OTHER" }, { "name": "ECG", "type": "DIAGNOSTIC_TEST" }, { "name": "ECHO", "type": "DIAGNOSTIC_TEST" }, { "name": "MUGA", "type": "DIAGNOSTIC_TEST" }, { "name": "DEXA", "type": "DIAGNOSTIC_TEST" }, { "name": "CT chest", "type": "DIAGNOSTIC_TEST" }, { "name": "PET", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "BM aspirate", "type": "PROCEDURE" }, { "name": "BM biopsy", "type": "PROCEDURE" }, { "name": "Lumbar puncture", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "OTHER", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2015-09-24", "completion_date": "2025-03-25", "has_results": true, "last_update_posted_date": "2025-09-30", "last_synced_at": "2026-09-25T22:23:35.654Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Minneapolis, Minnesota", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02356159" }, { "nct_id": "NCT06992427", "title": "High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8" ], "interventions": [ { "name": "Gabapentin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Chemotheraphy", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Analgesic Agent", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 228, "start_date": "2025-06-05", "completion_date": "2031-04-15", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-09-25T22:23:35.654Z", "location_count": 200, "location_summary": "Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 162 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06992427" }, { "nct_id": "NCT03974932", "title": "Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Analgesia" ], "interventions": [ { "name": "HTX-011", "type": "DRUG" }, { "name": "Ibuprofen", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "+/- Bupivacaine HCl", "type": "DRUG" }, { "name": "Luer Lock Applicator", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Heron Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2019-06-05", "completion_date": "2021-01-07", "has_results": true, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-09-25T22:23:35.654Z", "location_count": 6, "location_summary": "Sheffield, Alabama • Tamarac, Florida • Dayton, Ohio + 3 more", "locations": [ { "city": "Sheffield", "state": "Alabama" }, { "city": "Tamarac", "state": "Florida" }, { "city": "Dayton", "state": "Ohio" }, { "city": "Bellaire", "state": "Texas" }, { "city": "Plano", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03974932" }, { "nct_id": "NCT02028559", "title": "Safety and Effectiveness of the Ultrasonic Propulsion of Kidney Stones", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Kidney Stones", "Nephrolithiasis", "Urolithiasis" ], "interventions": [ { "name": "Propulse 1 with C5-2 probe", "type": "DEVICE" }, { "name": "Propulse 1 with SC-X probe", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 172, "start_date": "2013-12-17", "completion_date": "2026-05-31", "has_results": true, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-09-25T22:23:35.654Z", "location_count": 2, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02028559" }, { "nct_id": "NCT05511025", "title": "Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "AZD6234", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Acetaminophen", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 54, "start_date": "2022-09-20", "completion_date": "2023-12-19", "has_results": false, "last_update_posted_date": "2023-12-26", "last_synced_at": "2026-09-25T22:23:35.654Z", "location_count": 2, "location_summary": "Glendale, California • Brooklyn, Maryland", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Brooklyn", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05511025" }, { "nct_id": "NCT03414658", "title": "The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Utomilumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adrienne G. Waks", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2018-06-21", "completion_date": "2027-05-31", "has_results": true, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-09-25T22:23:35.654Z", "location_count": 17, "location_summary": "Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03414658" }, { "nct_id": "NCT01548690", "title": "Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Liver Failure", "Acute Liver Injury" ], "interventions": [ { "name": "Ornithine Phenylacetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "William Lee", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 47, "start_date": "2012-06", "completion_date": "2017-02-23", "has_results": true, "last_update_posted_date": "2018-10-30", "last_synced_at": "2026-09-25T22:23:35.654Z", "location_count": 11, "location_summary": "San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 8 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01548690" }, { "nct_id": "NCT07661459", "title": "Optimizing Ancillary Therapies With Immune Checkpoint Inhibitors for Solid Tumors (OAT ICI)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Asprin", "type": "DRUG" }, { "name": "Loratadine", "type": "DRUG" }, { "name": "Acetaminophen Avoidance", "type": "BEHAVIORAL" }, { "name": "THC Avoidance", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Val Adams", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 98, "start_date": "2026-06-26", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-09-25T22:23:35.654Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT07661459" }, { "nct_id": "NCT00579527", "title": "Phase I/II Thymus Transplantation With Immunosuppression #950", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "DiGeorge Anomaly", "Complete DiGeorge Anomaly", "Complete Atypical DiGeorge Anomaly", "Complete DiGeorge Syndrome", "Complete Atypical DiGeorge Syndrome" ], "interventions": [ { "name": "Cultured Thymus Tissue for Implantation (CTTI)", "type": "BIOLOGICAL" }, { "name": "Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation", "type": "OTHER" }, { "name": "Blood Draw", "type": "PROCEDURE" }, { "name": "Rabbit anti-thymocyte globulin", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Methylprednisolone or Prednisolone", "type": "DRUG" }, { "name": "Daclizumab", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "PROCEDURE", "DRUG" ], "sponsor": "Sumitomo Pharma Switzerland GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 14, "start_date": "2005-12-19", "completion_date": "2017-12-31", "has_results": true, "last_update_posted_date": "2022-03-25", "last_synced_at": "2026-09-25T22:23:35.654Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00579527" } ] }